 | The revision history of this page may contain copyright violations. Certain historical revisions of this page may meet criterion RD1 for revision deletion, as they contain significant copyright violations of https://kipdf.com/the-organic-chemistry-of-drug-synthesis_5b11589f7f8b9a58348b4598.html ( Copyvios report ) that have been removed in the meantime.
Note to admins: In case of doubt, remove this template and post a message asking for review at WT:CP. With this script, go to the history with auto-selected revisions. Note to the requestor: Make sure the page has already been reverted to a non-infringing revision or that infringing text has been removed or replaced before submitting this request. This template is reserved for obvious cases only, for other cases refer to Wikipedia:Copyright problems. Note to others: Please do not remove this template until an administrator has reviewed it. |
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C28H35NO4 |
| Molar mass | 449.591 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Asoprisnil (INN; developmental code name J-867) is a synthetic, steroidal selective progesterone receptor modulator that was under development by Schering and TAP Pharmaceutical Products for the treatment of uterine fibroids. [1] In 2005, phase III clinical trials were discontinued due to endometrial changes in patients. [2]
